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Objectives: We investigated the demographic characteristics, clinical and laboratory ﬁndings, treatment
strategies and clinical outcomes of patients presenting at emergency department (ED) with digoxin
levels at or above 1.2 ng/ml.
Materials and methods: The demographic and clinical characteristics of patients with serum digoxin
levels at or above 1.2 ng/ml admitted to an ED between January 2010 and July 2011 were investigated in
this cross-sectional descriptive study. Patients with ECG and clinical ﬁndings consistent with digoxin
toxicity and no additional explanation of their symptoms were evaluated for digoxin toxicity.
Results: In this study 137 patients were included, and 68.6% of patients were women with mean age
76.1 ± 12.2. There was no signiﬁcant difference between gender and digoxin intoxication. The mean age
of intoxicated group was signiﬁcantly higher than the non-intoxicated group (P ¼ 0.03). The most
common comorbidities were congestive heart failure (n ¼ 91) and atrial ﬁbrillation (n ¼ 74). The most
common symptoms were nausea, vomiting and abdominal pain. The levels of hospitalization and
mortality in this group were signiﬁcantly higher.
Conclusion: Digoxin intoxication must be suspected in patients present in the ED, particularly those with
complaints that include nausea and vomiting, as well as new ECG changes; serum digoxin levels must be
determined.
Copyright © 2016 The Emergency Medicine Association of Turkey. Production and hosting by Elsevier
B.V. on behalf of the Owner. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Despite the introduction of new drug classes for managing
congestive heart failure (CHF) and atrial ﬁbrillation (AF), many
patients admitted to emergency departments (EDs) continue to be
managed with cardiac glycosides. Cardiotoxicity from cardiac gly-
cosides may present obvious symptoms, such as nausea, vomiting,
and hypotension, or may be more subtle with nonspeciﬁc symp-
toms.1 The difﬁculty in diagnosing patients with digitalis intoxi-
cation can be attributed to several factors: 1) the signs, symptoms
and electrocardiogram (ECG) manifestations can be attributed to
the underlying disease process for which the drug is prescribed; 2)
the narrow therapeutic window of digoxin, which causes great905055252652 (mobile).
on).
ncy Medicine Association of
e Association of Turkey. Production
ons.org/licenses/by-nc-nd/4.0/).variability in the sensitivity of individuals toward the drug; 3) the
lack of any dysrhythmia diagnostic of toxicity.2,3 Chronic toxicity
occurs in 4e10% of the patients taking digitalis but is suspected in
only 0.25% of all cases4,5
Few studies have probed the incidence of toxicity and the factors
that affect the toxicity observed among patients presenting to ED,
despite the clinical importance of digoxin toxicity. We enacted this
cross-sectional retrospective study to investigate the demographic
characteristics, clinical and laboratory ﬁndings, treatment strate-
gies and clinical outcome of patients presenting at our ED whose
digoxin levels were 1.2 ng/ml or above. The threshold 1.2 ng/ml is
adopted because of the reported increased mortality above 1.2 ng/
ml in the study of Rathore et al.62. Materials and methods
This cross-sectional, descriptive review included the cases with
digoxin levels at or above 1.2 ng/ml at an ED between January 2010and hosting by Elsevier B.V. on behalf of the Owner. This is an open access article
Fig. 1. Algorithm for the study population.
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information system according to their digoxin levels regardless of
the presenting clinical symptoms or ﬁndings. Patients with missing
data were excluded from the study.
The study protocol was approved by the ethics committee
and was conducted in accordance with the Declaration of
Helsinki.
The day of admittance (day/month/year), as well as the ages,
genders, states of acute or chronic drug intake, comorbidities,
clinical ﬁndings, test results (ECG, as well as laboratory ﬁndings for
glucose, blood urea nitrogen, creatinine, sodium, potassium, chlo-
rine, complete blood count, CK-MB, troponin), treatment informa-
tion, blood digoxin levels and clinical outcomes, of the patients
were recorded using standard data forms.
Patients with ECG and clinical ﬁndings consistent with digoxin
toxicity and for whom there was no additional explanation of
symptoms were evaluated as suffering from digoxin toxicity.
Digoxin toxicity was studied based on acute or chronic usage, as
listed below.
Acute toxicity is indicated by the following:
1. The presence of dysrhythmias, dysrhythmias with decreased AV
conduction or/and increased automaticity (e.g., AF with AV
block, accelerated junctional rhythm), premature ventricular
contractions (PVCs) (particularly bigeminy or trigeminy) or
supraventricular tachyarrhythmias with rapid ventricular rates.7
2. Hyperkalemia (5.5 mEq/L).8
3. Probable clinical ﬁndings other than cardiac ﬁndings.3
Chronic toxicity is indicated by the following:
1. Bradyarrhythmias (may be ventricular tachyarrhythmias)
2. Normal to low serum potassium levels (may be high)8
3. Increased serum digoxin levels (expected therapeutic level
<1.2 ng/ml)6
4. Probable clinical ﬁndings other than the cardiac ﬁndings include
the following;
a. Weakness
b. Gastrointestinal system: anorexia, nausea, vomiting or
abdominal pain
c. Central nervous system: headache, thoughtfulness, halluci-
nations, delirium or photophobia, visual disturbances (yel-
low-green dyschromatopsia)3Table 1
The relationship between elevated digoxin levels and comorbid diseases.
Comorbid disease Digoxin toxicity p X2
Yes % No %
CHF 27 65.9 64 66.7 >0.05 0.03
AF 26 63.4 48 50 >0.05 2.75
HT 23 56.1 48 50 >0.05 0.73
CAD 13 31.7 27 28.1 >0.05 0.29
Other 10 24.4 37 37.5 >0.05 2.17
DM 9 21.9 22 22.9 >0.05 0.01
Cardiac valve disease 4 0.9 14 14.6 >0.05 0.492.1. Statistical analysis
The data recorded in Statistical Package for the Social Sciences
(SPSS) 16 for Windows statistical software (SPSS Inc., Chicago, IL,
USA). The qualitative variables are expressed as a % and the esti-
mation of 95% conﬁdence interval (CI). The quantitative variables
are expressed as the mean ± S.D. The means were compared using
Student's t-test or the ManneWhitney U-test as applicable after
verifying normality using the KolmogoroveSmirnov test. The as-
sociation of qualitative variables was made using the Chi-square
test. Test results with p values <0.05 were determined to be sta-
tistically signiﬁcant.
3. Results
During the study period, 124.557 patients arrived at the ED; 139
patients had digoxin levels 1.2 ng/ml or higher. Two of the patients
were excluded from the study due to a lack of data, and 137 patients
were included. The patients included in the studyaccounted for 0.11%
of the patients who arrived at the ED during the study period (Fig. 1).Among the patients included in the study, 43 (31.4%) were male,
and 94 (68.6%) were female; the mean age was 76.1 ± 12.2. The
youngest patient was 20, and the oldest patient was 104 years old.
Two (1.5%) patients arrived after acute oral intake, one patient
(0.7%) had with acute exposure during chronic intake and 134
(97.8%) patients were chronic users. The mean ages of the patients
with acute and chronic intake were 57.5 ± 50.2 and 76.3 ± 11.3,
respectively. There was no signiﬁcant difference between the age
groups (P > 0.05). Digoxinwas the only drug taken by 135 (98.5%) of
the patients. The exposures occurred with oral intake.
When evaluated using the clinical, laboratory and ECG ﬁndings,
29.9% (n ¼ 41) of patients were considered to have digoxin toxicity,
and 70.1% (n ¼ 96) of the patients only had high blood digoxin
levels but were not intoxicated. In the intoxicated group, one pa-
tient presented with acute toxicity, and 39 presented with chronic
toxicity. There was no signiﬁcant difference between the intoxi-
cated and non-intoxicated groups in the context of gender
(P > 0.05). The mean age of intoxicated group was signiﬁcantly
higher than that of the non-intoxicated group (79.8 ± 11.8 and
74.6 ± 12.1, respectively, P ¼ 0.03). No signiﬁcant differences were
found between the comorbid diseases of the patients and digoxin
toxicity (Table 1).
We found that the most common ﬁnal diagnoses other than
digoxin intoxicationwere CHF (n¼ 24,17.5%) and acute renal failure
(n¼ 13, 9.4%). Sixteen (11.6%) patients hadmore than one diagnosis
(Table 2).
The potassium level is signiﬁcantly higher in the intoxicated
group when the biochemical markers are evaluated (Table 3).
Table 2
The ﬁnal diagnoses of patients other than that of digoxin intoxication by system.
System N %
Cardiovascular 31 22.6
Pulmonary 18 13.1
Genitourinary 16 11.6
Gastrointestinal 12 8.7
Neurological 7 5.1
Other 34 24.8
Table 3
Laboratory values in both intoxicated and non-intoxicated patients.
Digoxin intoxication Yes No
N Mean N Mean P
Blood digoxin (ng/ml) 41 3.35 96 1.7 0.00
BUN (mg/dl) 41 43.5 95 35 >0.05
creatinine (mg/dl) 41 1.8 95 1.5 >0.05
Sodium (mmol/L) 41 135.5 95 135.5 >0.05
Potassium (mmol/L) 41 5.0 95 4.5 <0.05
Chloride (mmol//L) 41 103.9 95 102.7 >0.05
White blood cell (10X103/L) 41 10.8 95 11.2 >0.05
Glucose (mg/dl) 40 138.8 92 156.9 >0.05
Hemoglobin (g/dL) 41 11.8 94 11.8 >0.05
CKMB (ng/ml) 35 2.4 78 2.8 >0.05
Troponin (ng/ml) 35 0.3 78 0.3 >0.05
G. Limon et al. / Turkish Journal of Emergency Medicine 16 (2016) 17e21 19In the intoxicated group, the most common diagnoses included
cardiac symptoms and the most common symptoms included
nausea, vomiting, abdominal pain, altered mental status and visual
disturbances, respectively (35%; 27.5%; 20%; 7.5%).
Moreover, of the 41 patients with digoxin intoxication, 11
(26.8%) displayed no ECG changes, and 17 (41.5%) had new ECG
ﬁndings. Past ECGs could not be found for 13 (31.7%) patients. Of the
96 non-intoxicated patients, 73 (76.1%) displayed no ECG changes,
and 7 (7.3%) patients had new ECG ﬁndings. Past ECGs could not be
found for 16 (16.6%) patients. AF with slow ventricular rates, sinus
bradycardia and PVCs were signiﬁcantly more common in intoxi-
cated patients, while AF with a rapid ventricular rate was signiﬁ-
cantly more common in non-intoxicated patients (Table 4).
In the intoxicated group, the treatment modalities were
assessed. Coexisting diseases were treated in 18 patients (43.9%).
Supportive treatment was administered to 15 patients (36.6%).
Eleven patients (26.8%) were treated by pacemaker. Gastric lavage
and active charcoal was administered to one patient (2.4%).
During our study, 10.2% of patients died in the ED, while 21.9%
were admitted to intensive care units (Table 5). There wereTable 4
ECG ﬁndings for intoxicated and non-intoxicated patients.
ECG ﬁnding Digoxin intoxication
Yes % No % P X2
AF with slow ventricular rate 19 46.3 3 3.1 <0.01 41.43
AF with normal ventricular rate 11 26.8 37 37.5 >0.05 1.73
Left bundle branch block 6 14.6 12 12.5 >0.05 0.17
PVCs 5 12.2 1 1.1 0.03 8.90
Normal 4 9.8 14 14.6 >0.05 0.59
Sinus bradycardia 3 7.3 1 1.1 0.04 4.18
Right bundle branch block 2 4.8 2 2.2 >0.05 0.86
Sinus tachycardia 1 2.4 9 9.4 >0.05 2.04
Atrial premature beat 1 2.4 1 1.1 >0.05 0.43
First degree AV block 1 2.4 0 0 >0.05 2.43
Second-third degree AV block 0 0 1 1.1 >0.05 0.41
AF with rapid ventricular rate 0 0 20 20.8 <0.01 9.65
Atrial ﬂutter 0 0 1 1.1 >0.05 0.42
Bold: Statistically signiﬁcant values (p<0.05).signiﬁcant differences in the hospitalization, discharge and death of
the intoxicated versus the non-intoxicated patients (p < 0.001).
Hospitalization was signiﬁcantly more common among intoxicated
patient. However, there were no signiﬁcant differences between
the two groups in the context of the ﬁnal clinical courses (p¼ 0.82).
Among the hospitalized patients in the intoxicated group; two
of them died, and 20 of themwere discharged. The clinical courses
of 3 patients could not be found. Among the hospitalized patients in
the non-intoxicated group, 19 were discharged, 5 patients died and
the clinical courses of 6 patients could not be found. There were
signiﬁcant differences in the hospitalizations, discharges and
deaths between the intoxicated and non-intoxicated patients
(p < 0.001). Hospitalizationwas signiﬁcantly more common among
the intoxicated patients. However, there was no signiﬁcant differ-
ence between two groups relative to the ﬁnal clinical courses (Chi-
square:0.39; p ¼ 0.82).
Regarding the ﬁnal clinical outcomes of the patients, 107 (78.1%)
were discharged from the hospital, and 21 (15.3%) died. Among the
patients who died, 14 patients died in the ED, and 7 patients died
during hospitalization. All patients who died were chronic digoxin
users. The outcomes of 9 (6.6%) patients could not be found.
4. Discussion
The incidence of digoxin toxicity has declined recently due to
the decreased use of digoxin while treating heart failure and ar-
rhythmias, fast and accurate detection of drug levels and increased
awareness of the interactions between digoxin and other drugs.
Haynes et al reported a decrease in digoxin intoxication related to
the decreased use of digoxin between 1994 and 2004 in the USA.5
The American Association of Poison Control Centers reported 2610
toxic digoxin exposures in 2006, and this number was 2550 in
2009.9 Budnitz et al found that every arrival to the ED was drug
related among patients more than 65 years old. Moreover, 3.1% of
the patients were using digoxin, and 0.024% were diagnosed with
digoxin intoxication in the same study.10 Aarnoudse et al reported
in a study in which all presentations to the hospital were evaluated
that 0.04% of all presentations were attributed to digoxin intoxi-
cation.11 In our study, the patients for whom digoxin levels had
been obtained accounted for 0.068% of all presentations to the ED.
Similarly, patients who were diagnosed with digoxin intoxication
accounted for 0.032% of the patients who arrived at the ED at the
same time. This ratio was similar to that in the other studies.
Digoxin related emergency admissions are signiﬁcant causes of
drug-related presentations to the ED, particularly among the
elderly. Budnitz et al reported that the probability of hospitaliza-
tions related to drugs was 7-fold higher in patients above 65 years
of age.10 In another study, Butnitz et al evaluated drug related ED
presentations in patients older than 65, ﬁnding that the most
common drug related presentations were attributed to warfarin,
insulin and digoxin; these three drugs were 35-fold more common
among ED presentations because they are frequently prescribed.12
Miura et al found an increased sensitivity toward digoxin with
increasing age.13 During our study, themean age of the patients was
76.1 ± 12.2. Because digoxin use is more common among the
elderly, this result was expected. The mean ages of the digoxin-
intoxicated and non-intoxicated groups were 79.8 ± 11.8 and
74.6 ± 12.1, respectively. The mean age of the intoxicated groupwas
signiﬁcantly higher (p ¼ 0.03). This result supports other studies
showing that digoxin toxicity increases with age.10,12e14
Response toward digoxin treatment differs between genders.
Digoxin-related deaths are more common in females.15 Aarnoudse
et al reported that digoxin intoxication was 1.4-fold higher among
women while studying patients hospitalized related to digoxin
intoxication.11 In our study, 73.2% of the intoxicated group was
Table 5
Clinical outcomes of the patients in the ED.
Clinical outcomes Digoxin intoxication (þ) Digoxin intoxication () Total
N % n % n %
Discharged 12 29.3 56 58.3 68 49.6
Admitted to intensive care unit 20 48.8 10 10.4 30 21.9
Admitted to others services 4 9.8 15 15.6 19 13.9
Death 4 9.8 10 10.4 14 10.2
Self-discharge/refused the treatment 1 2.3 5 5.3 6 4.4
G. Limon et al. / Turkish Journal of Emergency Medicine 16 (2016) 17e2120female. No signiﬁcant difference was found between digoxin
intoxication and gender. However, we believe that the risk of
digoxin intoxication must be considered for every woman using
digoxin. Studies using a sex-separated genotype might elucidate
the sensitivity toward intoxication before use.
The majority of digoxin intoxications occurred in chronic
digoxin users. Pita-Fernandez et al found that most exposures were
due to taking an inappropriate dose of the drug; and only 4.8% of
the cases arose from accidentally intake.16 Suicidal drug ingestion is
commonly reported in the literature.17,18 According to Antman and
al, among 150 life-threatening digoxin intoxications, 50% of the
patients were long-term users, 10% of the patients took digoxin
accidentally, while 39% of patients took digoxin with suicidal
intent.19 In our study, 1.5% of the patients presented with acute
intake, 0.7% with acute exposure during chronic intake and 97.8%
were chronic users. In the intoxicated group, 95% were chronic
users, 2.4% presented with acute intake and 2.4% presented with
acute exposure during chronic intake. These results were similar to
those of Pita-Fernandez et al but the rate of acute intake was much
lower compared to the study of Antman et al. Unsurprisingly,
Antman et al reported more acute intakes because they investi-
gated life-threatening digoxin intoxications. The ages of the pa-
tients with acute intake ranged from 22 to 93, and the digoxin
levels were 12.2 ng/ml and 1.42 ng/l, respectively. Only one of their
results was consistent with digoxin intoxication. We found that
type of exposures had a signiﬁcant effect on blood digoxin levels
but had no effect on any other laboratory parameters.
Digoxin is usually used to control AF and CHF. Digoxin is safe,
particularly in males with decreased left ventricle function.15,18
Cardiac valvulopathy was detected in 81% of patients, HT was
found in 68.3% and ischemic heart diseasewas found in 46.3% in the
study by Pita-Fernandez et al; these researchers evaluated digoxin
intoxications in the elderly in EDs.16 We found that 66% of patients
had CHF, and 63% had AF among the digoxin intoxicated patients.
This was an expected result because CHF and AF are the most
common indications for digoxin use. We could not detect the
prevalence of valvulopathy possibly because our study was retro-
spective, precluding further examinations.
Mahdyoon et al reported that 43 patients had deﬁnite diagnoses
of digoxin intoxication, while 52% of patients had nausea, while 48%
suffered fromvomiting in a study including 219 patients discharged
from a hospital with a diagnosis of digital intoxication.20 Nausea
and vomiting were the most common complaints in the study by
Pita-Fernandez et al.16 In our study, the most common symptoms
among the 41 digoxin intoxicated patients were nausea and vom-
iting (35%), as well as abdominal pain (27.5%), similar to the
literature.
ECG ﬁndings are critical for diagnosing and treating digoxin
toxicity. There are differences between the ECG ﬁndings in various
studies. Ma et al reported that the most common ECG ﬁnding was
PVCs.7 Mahdyoon et al found the most common ECG ﬁndings were
AV block (66%) and sinus bradycardia (26%).20 Pita-Fernandez et al
found that, among 42 digoxin intoxicated patients, the most com-
mon ECG ﬁnding was AF (85%), and 45% of the patients had a theheart rate below 60/min.16 In our study the most common ECG
ﬁndings were AF with a slow ventricular rate (46.3%), AF with
normal ventricular rate (26.8%) and left bundle branch block
(14.6%), respectively. PVCs were detected in 12.2% of the patients.
Compared to non-intoxicated patients, sinus bradycardia, AF with a
slow ventricular rate and PVCs were signiﬁcantly more common in
the digoxin intoxicated group. Ordog et al found that among 5100
patients using digoxin, 65 patients had new ECG changes consistent
with digoxin toxicity.21 In our study, 41.5% of patients had new ECG
changes. ECG changes weremore common in our study because we
only investigated patients with elevated digoxin levels.
Digoxin is a safe antiarrhythmic agent in patients with AF ac-
cording to the current literature. However, in many studies
regarding the safety proﬁle of digoxin, the observation period is
short, and patients with CHF were excluded from the study.22
However, long-term studies are needed to evaluate the effects of
the ECG changes on mortality and morbidity. We believe that
digoxin levels must be observed in patients who use digoxin and
who have sinus bradycardia after they arrive at the ED for any
reason, AF with a slow ventricular rate or ventricular extra beats on
the ECG and digoxin intoxication must be considered in the light of
the laboratory and clinical ﬁndings.
The mean BUN levels were signiﬁcantly higher in the intoxi-
cated group, but there was no signiﬁcant difference in the potas-
sium levels of the intoxicated and non-intoxicated groups, as
observed by Smith et al.23 Renal failure was more common in the
intoxicated group, according to Beller et al.24 However, we did not
ﬁnd any signiﬁcant difference regarding the BUN and creatinine
levels between the two groups (Table 3).
The most common precipitating factor for digoxin intoxication
was usually the decrease in potassium stores due to diuretic
treatment and secondary hyperaldosteronism in patients with
heart failure.25 Therefore, hypokalemia is more common in intox-
ication related to chronic digoxin treatment.2 The blood potassium
levels were signiﬁcantly higher in the intoxicated group during our
study. Hyperkalemia is not expected during chronic digoxin
intoxication unless there is simultaneous renal failure.2 However,
most of the patients had chronic digoxin intoxication most likely
due to the frequent use of thiazide diuretics in patients with CHF
and HT; it is impossible to comment on the relationship between
drugs and high potassium levels because these drugs were not
assessed in our study.
Active charcoal administration and gastric lavage are the
gastrointestinal decontamination methods used to counter many
types of intoxications. The decontamination rates are lower in the
poison papers by AACT and EAPCCT after 1997 because the guide-
lines for administering a gastric lavage and active charcoal were
published after this date.26,27 Active charcoal may be useful during
the early stages of acute digoxin intake.28 Gastric lavage and active
charcoal were administered to one patient in our study; this patient
presented with acute digoxin toxicity. Most of the patients had
chronic digoxin intoxication, and this result is consistent with the
recent literature. One patient (0.7%) underwent hemodialysis for
hyperkalemia. Because of their comorbid diseases or ongoing
G. Limon et al. / Turkish Journal of Emergency Medicine 16 (2016) 17e21 21metabolic situations, 64.2% of patients (n ¼ 88) received other
therapies.
Different results have been reported in the literature regarding
the prognosis of digoxin intoxication. No deaths were reported by
Pita-Fernandez et al.16 However, 16% of the patients with digoxin
intoxication observed by Pap et al and 41% of patients with digoxin
intoxication observed by Mahdyoon et al died.14,20 In our study, in-
hospitalmortality occurred for 15% of the digoxin intoxicated group.
The differentmortality rates in these studies can be attributed to the
heterogeneity of the patients with digoxin intoxication and the lack
of standardized digoxin intoxication criteria. However, in our study
therewas a signiﬁcant difference between twogroups regarding the
admission to care units or services, as well as discharge or death.
Predicting the cause of mortality was difﬁcult because digoxin
intoxicated patientswere often elderlyandhad co-existing diseases.
Pita-Fernandez et al reported that 78.6% of the patients with
digoxin toxicity were hospitalized, while 85.7% of patients received
only symptomatic treatment; there were no deaths in the ED.16
Ordog et al reported that 24% of the patients were evaluated and
treated in the ED, and the others were hospitalized.21 In our study,
29.3% of patients were treated in the ED, 9.8% of patients died in the
ED and 58.6% of the patients were admitted to the hospital. In
addition, 48.8% of the hospitalized patients were admitted to
intensive care units. The rate of patients treated in the ED was
similar to that of Ordog et al, but the rate of hospitalization was
lower, indicating that a number of patients who should have been
hospitalized were treated in the ED.
5. Conclusions
We concluded that digoxin intoxication must be suspected in
patients presenting to the ED, particularly those complaining of
nausea and vomiting and exhibiting new electrocardiographic
changes. In these cases, the serum digoxin levels must be assessed.
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